7.77
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Low
0.6018
High
10.15
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Scynexis Inc | SCYX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 7.77 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.77 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 4.38 | 8.50 | 4.12 | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 7.77 | USD |
Scynexis Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 149.81M | 19.28M | 17.32M | $ 121.00k | $ - | -9.79 | -2.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Scynexis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCYX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.40 | 8.70 | 7.65 | 8.00 | 234,390 | -0.63 | -7.5% |
| 1 Month | 8.25 | 8.76 | 7.01 | 8.10 | 309,331 | -0.48 | -5.82% |
| 3 Months | 8.86 | 10.15 | 6.75 | 8.30 | 662,371 | -1.09 | -12.3% |
| 6 Months | 5.25 | 10.15 | 4.25 | 7.88 | 449,541 | 2.52 | 48.0% |
| 1 Year | 0.99 | 10.15 | 0.6018 | 3.86 | 543,257 | 6.78 | 684.85% |
| 3 Years | 1.28 | 10.15 | 0.35 | 1.97 | 618,932 | 6.49 | 507.03% |
| 5 Years | 4.1716 | 10.15 | 0.35 | 2.17 | 524,132 | 3.60 | 86.26% |
Scynexis Description
| SCYNEXIS Inc is drug development company which focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing lead product candidate, SCY-078 which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The SCY-078 is a novel and structurally distinct triterpenoid glucan synthase inhibitor which is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. |
